Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Current Deferred Revenue (2019 - 2025)

Outset Medical (OM) has disclosed Current Deferred Revenue for 7 consecutive years, with $13.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 8.17% to $13.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.8 million, a 8.17% increase, with the full-year FY2025 number at $13.8 million, up 8.17% from a year prior.
  • Current Deferred Revenue was $13.8 million for Q4 2025 at Outset Medical, down from $14.9 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $14.9 million in Q3 2025 to a low of $3.5 million in Q1 2021.
  • A 5-year average of $10.0 million and a median of $10.8 million in 2023 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: surged 98.06% in 2021, then rose 2.73% in 2025.
  • Outset Medical's Current Deferred Revenue stood at $6.3 million in 2021, then surged by 36.62% to $8.7 million in 2022, then skyrocketed by 35.38% to $11.7 million in 2023, then rose by 8.75% to $12.8 million in 2024, then increased by 8.17% to $13.8 million in 2025.
  • Per Business Quant, the three most recent readings for OM's Current Deferred Revenue are $13.8 million (Q4 2025), $14.9 million (Q3 2025), and $14.0 million (Q2 2025).